πŸ”¬Deep Research

VTRS β€” Viatris Β· catalysts, narrative & risks

Β·27 sourcesVTRS forecast β†’

Viatris Inc. (NASDAQ: VTRS) β€” Research Snapshot as of 2026-10-03

Company Context

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania, created in November 2020 from the merger of Mylan and Pfizer's Upjohn division [26], [28]. It trades on NASDAQ under VTRS [26]. As of the October 2, 2026 close, the stock traded near $17.56–17.60 with a market capitalization of roughly $20.2 billion [11], [15], [27]. The company operates across four segments (Developed Markets, Greater China, JANZ, Emerging Markets) in generics, established brands, and innovative medicines [15], [28].

Recent Catalysts (July–October 2026)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’